Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Prostate Carcinoma: early-phase trial registry
5 of 30 indexed Recurrent Prostate Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 5 currently recruiting · #519 of 28,707 conditions by registered trial count
Recurrent Prostate Carcinoma: 30 US clinical trials tracked, 5 recruiting.
Recurrent Prostate Carcinoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition recurrent-prostate-carcinoma
OPEN 5 | RECR 17% | LATE 4 | EARLY 24 | RANK #519 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Prostate Carcinoma lists 5 open slots (17% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Prostate Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Prostate Carcinoma is recruiting below its size-band peers.
5 of 30 indexed trials (16.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Prostate Carcinoma research.
Jonsson Comprehensive Cancer Center accounts for 7 of 30 trials (23.3%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Prostate Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 30 trials that report a genuine target (sentinel values excluded). 21 of those (70%) plan for fewer than 100 participants.
-
Recurrent Prostate Carcinoma research is mostly interventional.
28 interventional and 2 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
University of Washington
NCT01050504
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
NCT06650579
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
City of Hope Medical Center
NCT05722288
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
NCT07202247
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04857502
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NRG Oncology
NCT03371719
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
NCT01786265
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
Jonsson Comprehensive Cancer Center
NCT03582774
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
City of Hope Medical Center
NCT04519879
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
NCT01251861
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
NCT03016741
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Mayo Clinic
NCT01953640
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
NCT04190446
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
NCT02312557
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
NCT02522715
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Mamta Parikh
NCT02807805
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
Jonsson Comprehensive Cancer Center
NCT04457232
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT03902951
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
Emory University
NCT05779943
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
University of Utah
NCT03796767
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT02881242
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Jonsson Comprehensive Cancer Center
NCT02940262
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
NCT00170157
Tivantinib in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT01519414
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
Jonsson Comprehensive Cancer Center
NCT03515577
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT02099864
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02601014
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
NCT01503229
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Stanford University
NCT02488070
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT02159950
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 20 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Prostate Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Prostate Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Prostate Carcinoma page
30 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Recurrent Prostate Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonsson Comprehensive Cancer Center sponsors the most Recurrent Prostate Carcinoma trials on record, review their full trial history before evaluating a specific study. See Jonsson Comprehensive Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Prostate Carcinoma condition card totals 30 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.